Bayer Confident in Outcomes of ROCKET AF Study A Cardiovascular and Renal Drugs Advisory Committee conference has been scheduled for September 8, 2011, to review the brand new Drug Application in america for rivaroxaban in preventing stroke and non-CNS systemic embolism in sufferers with atrial fibrillation. In preparation for the conference, the U levitra i sverige vardenafilsverige.com .S. Meals and Medication Administration reviewers possess recommended that data from the ROCKET AF trial evaluating rivaroxaban to warfarin usually do not present whether rivaroxaban is really as effective because of its proposed indication compared to warfarin when the latter can be used skillfully.
Bayer improvements provide solutions for the global issues of the future The Bayer Group is to help expand expand its research and advancement activities regardless of the current economic and financial meltdown. ‘The task now could be to set the proper course. Only through creativity can our business generate the growth that’s necessary to safeguard its sustained achievement,’ stated Werner Wenning, Chairman of the Plank of Administration of Bayer AG, within an address given before 130 journalists through the ‘Bayer’s Perspective on Advancement 2008’ press discussion board in Leverkusen.